Contattaci contattaci
Home / Investors / Biofarma signs the acquisition of US Pharma Lab
May 18th, 2023

Biofarma signs the acquisition of US Pharma Lab

Biofarma Group announces the creation of the first global CDMO fully focused on Nutraceuticals through the acquisition of US Pharma Lab, a premium and highly innovative US-based player

Milan, 18th May 2023 – Biofarma S.r.l. (“Biofarma Group”), controlled by Ardian together with the Scarpa family, announces that it has entered into a definitive agreement for the acquisition (the “Acquisition”) of 100% of US Pharma Lab, Inc. (“US Pharma Lab”) from its Founder and Chairman, Mr. Ashok Luhadia, its CEO, Mr. Amol Luhadia, as well as other members of the Luhadia family. To cement a partnership between Ardian, the Scarpa family and the Luhadia family, the current shareholders of US Pharma Lab will reinvest a significant portion of their proceeds into an indirect parent company of Biofarma Group.

Biofarma signs the acquisition of US Pharma Lab – Presentation

Biofarma signs the acquisition of US Pharma Lab – Press Release


Forward Looking Statements

This press release may include “forward-looking statements” within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding Biofarma’s intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.

This press release constitutes a public disclosure of inside information by Kepler S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.

© Biofarma Srl C.F. e P.IVA 02895910301
T. +39 0432 868711 F. +39 0432 868018
Via Castelliere, 2
33036 Mereto di Tomba (UD) Italy
Numero REA UD - 296214
Data di iscrizione al Registro delle
Imprese di UDINE: 01/07/2017
Numero d'iscrizione: 02895910301
Capitale sociale euro 3.000.000